reports
Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL)Rinatabart sesutecan (Rina-S®) continues to show encouraging antitumor activity in patients with advanced ovarian cancer in data presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer® (SGO) Tivdak® (tisotumab ved...
Millicom (Tigo) Q1 2025 Earnings Release
Millicom (Tigo) Q1 2025 Earnings Release Millicom (Tigo) Q1 2025 Earnings Release Luxembourg, May 8, 2025 – is pleased to announce its first quarter 2025 results. Please find below links to the Q1 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q1 2025 Highlights* Revenue $1.37 billion Operating profit $423 million, and Adjusted EBITDA $636 million Net income $193 million, including approximately $95 million in one-time gains Equity free cash flow $135 million, excluding $42 million of net proceeds from disposals - leverage 2.47x Robust c...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 28 to May 2, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulat...
Genmab to Submit Supplemental Biologics License Application (sBLA) to ...
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – (Nasdaq: GMAB) announced today its intention to submit in ...
Millicom (Tigo) notice of first quarter 2025 results and video confere...
Millicom (Tigo) notice of first quarter 2025 results and video conference Millicom (Tigo) notice of first quarter 2025 results and video conference Luxembourg, April 29, 2025 – Millicom expects to announce its first quarter 2025 results on May 8, 2025, via a press release. Millicom is planning to host a video conference for the global financial community on May 8, 2025, at 14:00 pm (Luxembourg) / 13:00 (London) / 08:00 (Miami). Registration for the interactive event is required at the following . Participants may also join the conference in listen-only mode by dialing any of the followi...
- Stefan Gauffin
Millicom (Buy, TP: USD39.00) - Solid underlying performance
We are a bit below consensus on service revenue, but believe this fully relates to Bolivia, where Millicom is set to report based on an assumed fair FX rate. Adjusting for this, we are in line with consensus on service revenue and EBITDA. We reiterate our BUY and have converted to a USD-based target price of USD39 (SEK375). The results are due at 12:00 CET on 8 May.
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 21 to April 25, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumu...
SEB informs Millicom (Tigo) it has completed the sale of shares
SEB informs Millicom (Tigo) it has completed the sale of shares SEB informs Millicom (Tigo) it has completed the sale of shares Luxembourg, April 23, 2025 – Millicom International Cellular S.A. (“Millicom”) completed the delisting of its Swedish Depositary Receipts (SDRs) from Nasdaq Stockholm on March 17, 2025, resulting in the Nasdaq Stock Market in the United States being the sole exchange where its common shares are listed. SEB, the SDR program custodian bank, informed Millicom today that it has completed the sale of approximately 5,110,103 shares underlying the SDRs that had not been...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 14 to April 18, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Acc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
DLTR DOLLAR TREE INC.
CVGW CALAVO GROWERS INC.
CAR AVIS BUDGET GROUP INC.
A AGILENT TECHNOLOGIES INC.
MSB MESABI TRUST
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
TATT TAT TECHNOLOGIES LTD.
IIIN INSTEEL INDUSTRIES INC.
SJT SAN JUAN BASIN ROYALTY TRUST
CHCI COMSTOCK HOLDING COMPANIES
SEZI SENZIME AB
ANAB ANAPTYSBIO INC.
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
FRAF FRANKLIN FINANCIAL SERVICES CO.
OVBC OHIO VALLEY BANC CORP
NEON NEONODE INC.
SMMT SUMMIT THERAPEUTICS INC
HTZ HERTZ GLOBAL HLDGS INC
MPTI M TRON INDUSTRIES INC
NUTX NUTEX HEALTH INC
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
VRM VROOM INC
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,23...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 7 to April 11, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumul...
Convening Notice for Annual General Meeting and Extraordinary General ...
Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A.Registered Address:148-150, Boulevard de la Pétrusse L-2330, Grand Duchy of Luxembourg– R.C.S. Luxembourg: B40630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Novote...
Genmab A/S Share Capital Reduction
Genmab A/S Share Capital Reduction Company Announcement COPENHAGEN, Denmark; April 10, 2025 – (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expectedly on Monday April 14, 2025. After the share capital reduction, t...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2360.00) - Looking beyond HexaBody-CD38
Following Johnson & Johnson’s decision not to opt in for HexaBody-CD38, our focus shifts to the Q1 results and pipeline. For Q1, we forecast sales c0.4% above consensus, an operating profit margin of 20.2% (consensus 20.1%), and net profit c0.7% above consensus. We believe the recent SGO data validates Rina-S as potentially best-in-class and expect a phase III trial in endometrial cancer in H2. We reiterate our BUY but have cut our target price to DKK2,360 (2,400).
Millicom (Tigo) releases its 2024 Annual Report, marking a year of tra...
Millicom (Tigo) releases its 2024 Annual Report, marking a year of transformation in Latin America’s telecommunications industry Millicom (Tigo) releases its 2024 Annual Report, marking a year of transformation in Latin America’s telecommunications industry Luxembourg, April 08, 2025 –Millicom, a leading provider of fixed and mobile services in Latin America, announces today the release of its 2024 Annual Report, which includes the standalone financial statements of Millicom International Cellular S.A. for the year 2024. This year’s report reflects a period of profound transformation for...
Transactions In Connection with Share Buy-back Program
Transactions In Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 31 to April 4, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumula...
Transactions With Shares and Linked Securities in Genmab A/S Made by M...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; April 1, 2025 – (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previo...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapyIn the global Phase 3 innovaTV 301 clinical trial TIVDAK demonstrated superior overall survival compared to chemotherapyTIVDAK is approved for the treatment of recurrent or metastatic cervical cancer in the European Union, United States and Japan ...
Transactions in connection with share buy-back program
Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 26 to March 28, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)March ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.